AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

Shares of IQVIA Holdings Inc. IQV slipped 8.79% to $143.22 Thursday, on what proved to be an all-around poor trading session ...

Products made here might still depend on materials from overseas. And they might be made on machines needing foreign replacement parts.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Fintel reports that on April 10, 2025, Barclays downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 58.50% Upside As of April 2, ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

IQVIA (IQV) stock, ICON (ICLR) stock, and Fortrea (FTRE) stock were downgraded at Barclays, citing impact from potential pharma tariffs. Read more here.

New appointees with Edwards Lifesciences, with Laya Healthcare, Kepak Group, Allianz, Cullen Communications and Ringers ...

Truist analyst Jailendra Singh lowered the firm’s price target on Iqvia (IQV) to $216 from $263 and keeps a Buy rating on the shares as part of ...